PriceSensitive

Ceapro (TSXV:CZO) appoints top executive from global pharmaceutical industry

Consumer, Health Care
TSXV:CZO
02 March 2022 16:30 (EDT)

Ceapro (CZO) has appointed international pharmaceutical industry executive, Ronnie Miller, to its board of directors.

With his appointment, Miller was granted options to get 150,000 common shares of Ceapro. Each grant vests in three equal installments, and, once vested, each option is exercisable for five years.

Gilles Gagnon, President and CEO of Ceapro commented on the appointment.

“We firmly believe that his business acumen combined with his successful business development track record and vast industry network will prove to be invaluable as we expand our business model though the development of natural products and technology platforms into the expansive nutraceutical and pharmaceutical markets.”

Miller brings more than 43 years of leadership experience in the pharmaceutical industry. Until recently he served as President and CEO of Hoffmann-La Roche Limited.

Prior to his appointment there, Miller oversaw successive sales and management positions across the industry for Roche in the United Kingdom in 1988 and continued to move globally as a product manager.

Miller commented,

“It is my great pleasure to join the Ceapro board of directors at this important time as the company expands its natural ingredient product expertise into additional potential therapeutic indications.”

Ceapro is a Canadian biotechnology company developing a proprietary extraction technology to produce extracts and “active ingredients” from oats and other renewable plant resources. The extracts are used in cosmeceutical, nutraceutical, and therapeutics products for humans and animals.

Ceapro Inc. (CZO) is unchanged trading at $0.43 per share as of 4:20 p.m. EST.

Related News